In vitro model systems to study androgen receptor signaling in prostate cancer

Endocrine-Related Cancer

Volumn 20, Issue 2, 2013, Pages

  Sampson, Natalie ^a   Neuwirt, Hannes ^a   Puhr, Martin ^a   Klocker, Helmut ^a   Eder, Iris E ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Castration resistant; Cell culture; Stroma; Three dimensional coculture; Tumor

Indexed keywords

ANDROGEN RECEPTOR;

CANCER GROWTH; CELL CULTURE; CELL LINE; HUMAN; IMMUNE SYSTEM; IN VITRO STUDY; NONHUMAN; PROSTATE CANCER; PROTEIN FUNCTION; REVIEW; STEM CELL; STROMA;

ANIMALS; CELL LINE; CELL LINE, TUMOR; HUMANS; MALE; NEOPLASTIC STEM CELLS; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION;

EID: 84876759566     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-12-0401     Document Type: Review

References (147)

1. Ao M, Franco OE, Park D, Raman D,Williams K & Hayward SW 2007 Crosstalk between paracrine-Acting cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium. Cancer Research 67 4244-4253. (doi:10.1158/0008-5472.CAN-06-3946)
2. Attardi BJ, Burgenson J, Hild SA & Reel JR 2004 Steroid hormonal regulation of growth, prostate specific antigen secretion, and transcription mediated by the mutated androgen receptor in CWR22Rv1 human prostate carcinoma cells. Molecular and Cellular Endocrinology 222 121-132. (doi:10.1016/j.mce. 2004.04.013)
3. Barclay WW, Woodruff RD, Hall MC & Cramer SD 2005 A system for studying epithelial-stromal interactions reveals distinct inductive abilities of stromal cells from benign prostatic hyperplasia and prostate cancer. Endocrinology 146 13-18. (doi:10.1210/en.2004-1123)
4. Barron DA & Rowley DR 2012 The reactive stroma microenvironment and prostate cancer progression. Endocrine-Related Cancer 19 R187-R204. (doi:10.1530/ERC-12-0085)
5. Bello D, Webber MM, Kleinman HK, Wartinger DD & Rhim JS 1997 Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. Carcinogenesis 18 1215-1223. (doi:10.1093/carcin/18.6.1215)
6. Bennett NC, Gardiner RA, Hooper JD, Johnson DW & Gobe GC 2012 Molecular cell biology of androgen receptor signalling. International Journal of Biochemistry & Cell Biology 42 813-827. (doi:10.1016/j.biocel. 2009.11.013)
7. Berry PA, Birnie R, Droop AP, Maitland NJ & Collins AT 2011 The calcium sensor STIM1 is regulated by androgens in prostate stromal cells. Prostate 71 1646-1655. (doi:10.1002/pros.21384)
8. Berthon P, Waller AS, Villette JM, Loridon L, Cussenot O & Maitland NJ 1997 Androgens are not a direct requirement for the proliferation of human prostatic epithelium in vitro. International Journal of Cancer 73 910-916. (doi:10.1002/(SICI)1097-0215(19971210)73:6!910::AIDIJC25O3.0.CO;2-6)
9. Bosland MC, Chung LW, Greenberg NM, Ho SM, Isaacs JT, Lane K, Peehl DM, Thompson TC, van Steenbrugge GJ & van Weerden WM 1996 Recent advances in the development of animal and cell culture models for prostate cancer research. A minireview. Urologic Oncology 2 99. (doi:10.1016/S1078-1439(96)00077-4)
10. Brinkmann AO 2011 Molecular mechanisms of androgen action -A historical perspective. Methods in Molecular Biology 776 3-24. (doi:10.1007/978-1-61779- 243-4-1)
11. Cano P, Godoy A, Escamilla R, Dhir R & Onate SA 2007 Stromal-epithelial cell interactions and androgen receptor-coregulator recruitment is altered in the tissue microenvironment of prostate cancer. Cancer Research 67 511-519. (doi:10.1158/0008-5472.CAN-06-1478)
12. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG & Sawyers CL 2004 Molecular determinants of resistance to antiandrogen therapy. Nature Medicine 10 33-39. (doi:10.1038/nm972)
13. Cheng H, Snoek R, Ghaidi F, Cox ME & Rennie PS 2006 Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression. Cancer Research 66 10613-10620. (doi:10.1158/0008- 5472.CAN-06-0028)
14. Cherian MT, Wilson EM & Shapiro DJ 2012 A competitive inhibitor that reduces recruitment of androgen receptor to androgen-responsive genes. Journal of Biological Chemistry 287 23368-23380. (doi:10.1074/jbc.M112.344671)
15. Chou YW, Chaturvedi NK, Ouyang S, Lin FF, Kaushik D, Wang J, Kim I & Lin MF 2011 Histone deacetylase inhibitor valproic acid suppresses the growth and increases the androgen responsiveness of prostate cancer cells. Cancer Letters 311 177-186. (doi:10.1016/j.canlet.2011.07.015)
16. Chung LW, Zhau HE & Wu TT 1997 Development of human prostate cancer models for chemoprevention and experimental therapeutics studies. Journal of Cellular Biochemistry. Supplement 28-29 174-181. (doi:10.1002/(SICI)1097- 4644(1997)28/29C!174::AID-JCB21O3.0.CO;2-G)
17. Chuu CP, Kokontis JM, Hiipakka RA, Fukuchi J, Lin HP, Lin CY, Huo C & Su LC 2011 Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer. Journal of Biomedical Science 18 63. (doi:10.1186/1423-0127-18-63)
18. Craft N, Shostak Y, CareyM& Sawyers CL 1999 A mechanismfor hormoneindependent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nature Medicine 5 280-285. (doi:10.1038/6495)
19. Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A, Bartsch G, Utermann G, Schneider MR, Parczyk K et al. 1999 Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system. British Journal of Cancer 81 242-251. (doi:10.1038/sj.bjc.6690684)
20. Cunha GR 2008 Mesenchymal-epithelial interactions: past, present, and future. Differentiation 76 578-586. (doi:10.1111/j.1432-0436.2008.x)
21. Cunha GR, Hayward SW& Wang YZ 2002 Role of stroma in carcinogenesis of the prostate. Differentiation 70 473-485. (doi:10.1046/j.1432-0436.700902.x)
22. Cunha GR, Hayward SW, Wang YZ & Ricke WA 2003 Role of the stromal microenvironment in carcinogenesis of the prostate. International Journal of Cancer 107 1-10. (doi:10.1002/ijc.11335)
23. Cunha GR, Ricke W, Thomson A, Marker PC, Risbridger G, Hayward SW, Wang YZ, Donjacour AA & Kurita T 2004 Hormonal, cellular, and molecular regulation of normal and neoplastic prostatic development. Journal of Steroid Biochemistry and Molecular Biology 92 221-236. (doi:10.1016/j.jsbmb.2004.10.017)
24. Cutress ML, Whitaker HC, Mills IG, Stewart M & Neal DE 2008 Structural basis for the nuclear import of the human androgen receptor. Journal of Cell Science 121 957-968. (doi:10.1242/jcs.022103)
25. D'Antonio JM, Vander Griend DJ, Antony L, Ndikuyeze G, Dalrymple SL, Koochekpour S & Isaacs JT 2010 Loss of androgen receptor-dependent growth suppression by prostate cancer cells can occur independently from acquiring oncogenic addiction to androgen receptor signaling. PLoS ONE 5 e11475. (doi:10.1371/journal.pone.0011475)
26. Deep G, Oberlies NH, Kroll DJ & Agarwal R 2008 Isosilybin B causes androgen receptor degradation in human prostate carcinoma cells via PI3K-Akt-Mdm2-mediated pathway. Oncogene 27 3986-3998. (doi:10.1038/onc.2008.45)
27. Dehm SM & Tindall DJ 2011 Alternatively spliced androgen receptor variants. Endocrine-Related Cancer 18 R183-R196. (doi:10.1530/ERC-11-0141)
28. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL & Tindall DJ 2008 Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Research 68 5469-5477. (doi:10.1158/0008-5472.CAN-08-0594)
29. Desiniotis A, Schafer G, Klocker H & Eder IE 2010 Enhanced antiproliferative and proapoptotic effects on prostate cancer cells by simultaneously inhibiting androgen receptor and cAMP-dependent protein kinase A. International Journal of Cancer 126 775-789. (doi:10.1002/ijc.24806)
30. Florczyk SJ, Liu G, Kievit FM, Lewis AM, Wu JD & ZhangM2012 3D porous chitosan-Alginate scaffolds: a new matrix for studying prostate cancer cell-lymphocyte interactions in vitro. Advanced Healthcare Materials 1 590-599. (doi:10.1002/adhm.201100054)
31. Gao M, Ossowski L & Ferrari AC 1999 Activation of Rb and decline in androgen receptor precede retinoic acid-induced apoptosis in androgen-dependent LNCaP cells and their androgen-independent derivative. Journal of Cellular Physiology 179 336-346. (doi:10.1002/(SICI)1097-4652(199906)179:3!336::AID- JCP11O3.0.CO;2-Q)
32. Grant ES, Batchelor KW & Habib FK 1996 Androgen independence of primary epithelial cultures of the prostate is associated with a down-regulation of androgen receptor gene expression. Prostate 29 339-349. (doi:10.1002/(SICI) 1097-0045(199612)29:6!339::AIDPROS1O3.0.CO;2-3)
33. Green SM, Mostaghel EA & Nelson PS 2012 Androgen action and metabolism in prostate cancer. Molecular and Cellular Endocrinology 360 3-13. (doi:10.1016/j.mce.2011.09.046)
34. Gu Y, Kim KH, Ko D, Srivastava S, Moul JW, McLeod DG & Rhim JS 2005 Androgen and androgen receptor antagonist responsive primary African-American benign prostate epithelial cell line. Anticancer Research 25 1-8.
35. Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, Kong X, Melamed J, Tepper CG, Kung HJ et al. 2009 A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Research 69 2305-2313. (doi:10.1158/0008- 5472.CAN-08-3795)
36. Gustavsson H, Welen K & Damber JE 2005 Transition of an androgendependent human prostate cancer cell line into an androgenindependent subline is associated with increased angiogenesis. Prostate 62 364-373. (doi:10.1002/pros.20145)
37. Harma V, Virtanen J, Makela R, Happonen A, Mpindi JP, Knuuttila M, Kohonen P, Lotjonen J, Kallioniemi O & NeesM2010 A comprehensive panel of three-dimensional models for studies of prostate cancer growth, invasion and drug responses. PLoS ONE 5 e10431. (doi:10.1371/journal.pone.0010431)
38. Hayward SW, Dahiya R, Cunha GR, Bartek J, Deshpande N & Narayan P 1995 Establishment and characterization of an immortalized but nontransformed human prostate epithelial cell line: BPH-1. In Vitro Cellular & Developmental Biology. Animal 31 14-24. (doi:10.1007/BF02631333)
39. Hayward SW, Wang Y, Cao M, Hom YK, Zhang B, Grossfeld GD, Sudilovsky D & Cunha GR 2001 Malignant transformation in a nontumorigenic human prostatic epithelial cell line. Cancer Research 61 8135-8142.
40. Hensley PJ & Kyprianou N 2012 Modeling prostate cancer in mice: limitations and opportunities. Journal of Andrology 33 133-144. (doi:10.2164/jandrol.111.013987)
41. Horoszewicz JS, Leong SS, Ming CT, Wajsman ZJ, Friedman M, Papsidero L, Kim U, Chai LS, Kakati S, Arya SK et al. 1980 The LNCaP cell line -A new model for studies on human prostate carcinoma. In Models for Prostate Cancer, pp 114-132. Ed GD Murphy. New York: Alan Liss. Hu R, Isaacs WB & Luo J 2011 A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities. Prostate 71 1656-1667. (doi:10.1002/pros.21382)
42. Igawa T, Lin FF, Lee MS, Karan D, Batra SK & Lin MF 2002 Establishment and characterization of androgen-independent human prostate cancer LNCaP cell model. Prostate 50 222-235. (doi:10.1002/pros.10054)
43. Ishikura N, Kawata H, Nishimoto A, Nakamura R, Ishii N & Aoki Y 2010 Establishment and characterization of an androgen receptordependent, androgen-independent human prostate cancer cell line, LNCaP-CS10. Prostate 70 457-466. (doi:10.1002/pros.21079)
44. Iwasa Y, Mizokami A, Miwa S, Koshida K & Namiki M 2007 Establishment and characterization of androgen-independent human prostate cancer cell lines, LN-REC4 and LNCaP-SF, from LNCaP. International Journal of Urology 14 233-239. (doi:10.1111/j.1442-2042.2007.01532.x)
45. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF & Jones LW 1979 Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Investigative Urology 17 16-23.
46. Karan D, Schmied BM, Dave BJ, Wittel UA, Lin MF & Batra SK 2001 Decreased androgen-responsive growth of human prostate cancer is associated with increased genetic alterations. Clinical Cancer Research 7 3472-3480.
47. Karlou M, Tzelepi V & Efstathiou E 2010 Therapeutic targeting of the prostate cancer microenvironment. Nature Reviews. Urology 7 494-509. (doi:10.1038/nrurol.2010.134)
48. KimW& Ryan CJ 2012 Androgen receptor directed therapies in castrationresistant metastatic prostate cancer. Current Treatment Options in Oncology 13 189-200. (doi:10.1007/s11864-012-0188-2)
49. Kim KH, Dobi A, Shaheduzzaman S, Gao CL, Masuda K, Li H, Drukier A, Gu Y, Srikantan V, Rhim JS et al. 2007 Characterization of the androgen receptor in a benign prostate tissue-derived human prostate epithelial cell line: RC-165N/human telomerase reverse transcriptase. Prostate Cancer and Prostatic Diseases 10 30-38. (doi:10.1038/sj.pcan.4500915)
50. Kim SH, Richardson M, Chinnakannu K, Bai VU, Menon M, Barrack ER & Reddy GP 2010 Androgen receptor interacts with telomeric proteins in prostate cancer cells. Journal of Biological Chemistry 285 10472-10476. (doi:10.1074/jbc.M109.098798)
51. Klein KA, Reiter RE, Redula J, Moradi H, Zhu XL, Brothman AR, Lamb DJ, Marcelli M, Belldegrun A,Witte ON et al. 1997 Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nature Medicine 3 402-408. (doi:10.1038/nm0497-402)
52. Knouf EC, Metzger MJ, Mitchell PS, Arroyo JD, Chevillet JR, Tewari M & Miller AD 2009 Multiple integrated copies and high-level production of the human retrovirus XMRV (xenotropic murine leukemia virusrelated virus) from 22Rv1 prostate carcinoma cells. Journal of Virology 83 7353-7356. (doi:10.1128/JVI.00546-09)
53. Kogan I, GoldfingerN,MilyavskyM, CohenM, Shats I, DoblerG, Klocker H, Wasylyk B, Voller M, Aalders T et al. 2006 hTERT-immortalized prostate epithelial and stromal-derived cells: an authentic in vitro model for differentiation and carcinogenesis. Cancer Research 66 3531-3540. (doi:10.1158/0008-5472.CAN-05-2183)
54. Kokontis J, Takamura K, Hay N & Liao S 1994 Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after longterm androgen deprivation. Cancer Research 54 1566-1573.
55. Kokontis JM, Hay N & Liao S 1998 Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. Molecular Endocrinology 12 941-953. (doi:10.1210/me.12.7.941)
56. Koochekpour S, Maresh GA, Katner A, Parker-Johnson K, Lee TJ, Hebert FE, Kao YS, Skinner J & Rayford W 2004 Establishment and characterization of a primary androgen-responsive African-American prostate cancer cell line, E006AA. Prostate 60 141-152. (doi:10.1002/pros.20053)
57. Korenchuk S, Lehr JE, MClean L, Lee YG, Whitney S, Vessella R, Lin DL & Pienta KJ 2001 VCaP, a cell-based model system of human prostate cancer. In Vivo 15 163-168.
58. Lamont KR & Tindall DJ 2010 Androgen regulation of gene expression. Advances in Cancer Research 107 137-162. (doi:10.1016/S0065-230X (10)07005-3)
59. Lamont KR & Tindall DJ 2011 Minireview: alternative activation pathways for the androgen receptor in prostate cancer. Molecular Endocrinology 25 897-907. (doi:10.1210/me.2010-0469)
60. Lang SH, Stark M, Collins A, Paul AB, Stower MJ & Maitland NJ 2001 Experimental prostate epithelial morphogenesis in response to stroma and three-dimensional matrigel culture. Cell Growth & Differentiation 12 631-640.
61. Lang SH, Smith J, Hyde C, Macintosh C, Stower M & Maitland NJ 2006 Differentiation of prostate epithelial cell cultures by matrigel/stromal cell glandular reconstruction. In Vitro Cellular & Developmental Biology. Animal 42 273-280. (doi:10.1290/0511080.1)
62. Laschak M, Spindler KD, Schrader AJ, Hessenauer A, Streicher W, Schrader M & Cronauer MV 2012 JS-K, a glutathione/glutathione S-transferase-Activated nitric oxide releasing prodrug inhibits androgen receptor and WNT-signaling in prostate cancer cells. BMC Cancer 12 130. (doi:10.1186/1471-2407-12-130)
63. Lee YG, Korenchuk S, Lehr J, Whitney S, Vessela R & Pienta KJ 2001 Establishment and characterization of a new human prostatic cancer cell line: DuCaP. In Vivo 15 157-162.
64. Lee SO, Ma Z, Yeh CR, Luo J, Lin TH, Lai KP, Yamashita S, Liang L, Tian J, Li L et al. 2013 New therapy targeting differential androgen receptor signaling in prostate cancer stem/progenitor vs non-stem/progenitor cells. Journal of Molecular Cell Biology 5 14-26. (doi:10.1093/jmcb/mjs042)
65. Li R, Evaul K, Sharma KK, Chang KH, Yoshimoto J, Liu J, Auchus RJ & Sharifi N 2012a Abiraterone inhibits 3b-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer. Clinical Cancer Research 18 3571-3579. (doi:10.1158/1078-0432.CCR-12-0908)
66. Li Y, Hwang TH, Oseth LA, Hauge A, Vessella RL, Schmechel SC, Hirsch B, Beckman KB, Silverstein KA & Dehm SM 2012b AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression. Oncogene 31 4759-4767. (doi:10.1038/onc.2011.637)
67. Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, Ettinger SL, GleaveME & Nelson CC 2008 Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Research 68 6407-6415. (doi:10.1158/0008-5472.CAN-07-5997)
68. Lu S, Tsai SY & Tsai MJ 1999 Molecular mechanisms of androgenindependent growth of human prostate cancer LNCaP-AI cells. Endocrinology 140 5054-5059. (doi:10.1210/en.140.11.5054)
69. Marcias G, Erdmann E, Lapouge G, Siebert C, Barthelemy P, Duclos B, Bergerat JP, Ceraline J & Kurtz JE 2010 Identification of novel truncated androgen receptor (AR) mutants including unreported pre-mRNA splicing variants in the 22Rv1 hormone-refractory prostate cancer (PCa) cell line. Human Mutation 31 74-80. (doi:10.1002/humu.21138)
70. Marcinkiewicz K, Scotland KB, Boorjian SA, Nilsson EM, Persson JL, Abrahamsson PA, Allegrucci C, Hughes IA, Gudas LJ & Mongan NP 2012 The androgen receptor and stem cell pathways in prostate and bladder cancers (review). International Journal of Oncology 40 5-12. (doi:10.3892/ijo.2011.1212)
71. Marques RB, Erkens-Schulze S, de Ridder CM, Hermans KG, Waltering K, Visakorpi T, Trapman J, Romijn JC, van WeerdenWM& Jenster G 2005 Androgen receptor modifications in prostate cancer cells upon longterm androgen ablation and antiandrogen treatment. International Journal of Cancer 117 221-229. (doi:10.1002/ijc.21201)
72. Marques RB, van Weerden WM, Erkens-Schulze S, de Ridder CM, Bangma CH, Trapman J & Jenster G 2006 The human PC346 xenograft and cell line panel: a model system for prostate cancer progression. European Urology 49 245-257. (doi:10.1016/j.eururo.2005.12.035)
73. Marques RB, Dits NF, Erkens-Schulze S, van WeerdenWM& Jenster G 2010 Bypass mechanisms of the androgen receptor pathway in therapyresistant prostate cancer cell models. PLoS ONE 5 e13500. (doi:10.1371/journal.pone.0013500)
74. Marques RB, Dits NF, Erkens-Schulze S, van IjckenWF, van WeerdenWM& Jenster G 2011 Modulation of androgen receptor signaling in hormonal therapy-resistant prostate cancer cell lines. PLoS ONE 6 e23144. (doi:10.1371/journal.pone.0023144)
75. McConkey DJ, Greene G & Pettaway CA 1996 Apoptosis resistance increases with metastatic potential in cells of the human LNCaP prostate carcinoma line. Cancer Research 56 5594-5599.
76. McCourt C, Maxwell P, Mazzucchelli R, Montironi R, Scarpelli M, Salto-Tellez M, O'Sullivan JM, Longley DB & Waugh DJ 2012 Elevation of c-FLIP in castrate-resistant prostate cancer antagonizes therapeutic response to androgen receptor-targeted therapy. Clinical Cancer Research 18 3822-3833. (doi:10.1158/1078-0432.CCR-11-3277)
77. McNamara KM, Handelsman DJ & Simanainen U 2012 The mouse as a model to investigate sex steroid metabolism in the normal and pathological prostate. Journal of Steroid Biochemistry and Molecular Biology 131 107-121. (doi:10.1016/j.jsbmb.2011.10.009)
78. Miki J & Rhim JS 2008 Prostate cell cultures as in vitro models for the study of normal stem cells and cancer stem cells. Prostate Cancer and Prostatic Diseases 11 32-39. (doi:10.1038/sj.pcan.4501018)
79. Mishra DK, Chen Z, Wu Y, Sarkissyan M, Koeffler HP & Vadgama JV 2010 Global methylation pattern of genes in androgen-sensitive and androgen-independent prostate cancer cells. Molecular Cancer Therapeutics 9 33-45. (doi:10.1158/1535-7163.MCT-09-0486)
80. Miyamoto H, Rahman MM & Chang C 2004 Molecular basis for the antiandrogen withdrawal syndrome. Journal of Cellular Biochemistry 91 3-12. (doi:10.1002/jcb.10757)
81. Mohler JL, Gregory CW, Ford OH, III, Kim D, Weaver CM, Petrusz P, Wilson EM & French FS 2004 The androgen axis in recurrent prostate cancer. Clinical Cancer Research 10 440-448. (doi:10.1158/1078-0432.CCR-1146-03)
82. Mohler ML, Coss CC, Duke CB, III, Patil SA, Miller DD & Dalton JT 2012 Androgen receptor antagonists: a patent review (2008-2011). Expert Opinion on Therapeutic Patents 22 541-565. (doi:10.1517/13543776.682571)
83. Molina A & Belldegrun A 2011 Novel therapeutic strategies for castration resistant prostate cancer: inhibition of persistent androgen production and androgen receptor mediated signaling. Journal of Urology 185 787-794. (doi:10.1016/j.juro.2010.10.042)
84. Navone NM, Olive M, Ozen M, Davis R, Troncoso P, Tu SM, Johnston D, Pollack A, Pathak S, von Eschenbach AC et al. 1997 Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clinical Cancer Research 3 2493-2500.
85. Niranjan B, Lawrence MG, Papargiris MM, Richards MG, Hussain S, Frydenberg M, Pedersen J, Taylor RA & Risbridger GP 2012 Primary culture and propagation of human prostate epithelial cells. Methods in Molecular Biology 945 365-382. (doi:10.1007/978-1-62703-125-7-22)
86. Nyquist MD & Dehm SM 2013 Interplay between genomic alterations and androgen receptor signaling during prostate cancer development and progression. Hormones & Cancer 4 61-69. (doi:10.1007/s12672-013-0131-4)
87. Oldridge EE, Pellacani D, Collins AT & Maitland NJ 2012 Prostate cancer stem cells: are they androgen-responsiveMolecular and Cellular Endocrinology 360 14-24. (doi:10.1016/j.mce.2011.07.008)
88. Paulo P, Ribeiro FR, Santos J, Mesquita D, Almeida M, Barros-Silva JD, Itkonen H, Henrique R, Jeronimo C, Sveen A et al. 2012 Molecular subtyping of primary prostate cancer reveals specific and shared target genes of different ETS rearrangements. Neoplasia 14 600-611.
89. Peehl DM 2005 Primary cell cultures as models of prostate cancer development. Endocrine-Related Cancer 12 19-47. (doi:10.1677/erc.1.
90. Pettaway CA, Pathak S, Greene G, Ramirez E, Wilson MR, Killion JJ & Fidler IJ 1996 Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. Clinical Cancer Research 2 1627-1636.
91. Pfeiffer MJ, Smit FP, Sedelaar JP & Schalken JA 2011 Steroidogenic enzymes and stem cell markers are upregulated during androgen deprivation in prostate cancer. Molecular Medicine 17 657-664. (doi:10.2119/molmed. 2010.00143)
92. Pfeil K, Eder IE, Putz T, Ramoner R, Culig Z, Ueberall F, Bartsch G & Klocker H 2004 Long-term androgen-Ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells. Prostate 58 259-268. (doi:10.1002/pros.10332)
93. Rahman M, Miyamoto H & Chang C 2004 Androgen receptor coregulators in prostate cancer: mechanisms and clinical implications. Clinical Cancer Research 10 2208-2219. (doi:10.1158/1078-0432.CCR-0746-3)
94. Reis LO 2011 Old issues and new perspectives on prostate cancer hormonal therapy: the molecular substratum. Medical Oncology 29 1948-1955. (doi:10.1007/s12032-011-9991-z)
95. Rhim JS, Li H & Furusato B 2011 Novel human prostate epithelial cell culture models for the study of carcinogenesis and of normal stem cells and cancer stem cells. Advances in Experimental Medicine and Biology 720 71-80. (doi:10.1007/978-1-4614-0254-1-6)
96. Ricke WA, Ishii K, Ricke EA, Simko J, Wang Y, Hayward SW & Cunha GR 2006 Steroid hormones stimulate human prostate cancer progression and metastasis. International Journal of Cancer 118 2123-2131. (doi:10.1002/ijc. 21614)
97. Robbins SE, Shu WP, Kirschenbaum A, Levine AC, MiniatiDN&LiuBC 1996 Bone extracellular matrix induces homeobox proteins independent of androgens: possible mechanism for androgen-independent growth in human prostate cancer cells. Prostate 29 362-370. (doi:10.1002/(SICI)1097-0045(199612)29:6!362::AID- PROS4O3.0.CO;2-A)
98. Sampson N, Untergasser G, Plas E & Berger P 2007 The ageing male reproductive tract. Journal of Pathology 211 206-218. (doi:10.1002/path.2077)
99. Sampson N, Koziel R, Zenzmaier C, Bubendorf L, Plas E, Jansen-Durr P & Berger P 2011 ROS signaling by NOX4 drives fibroblast-to-myofibroblast differentiation in the diseased prostatic stroma. Molecular Endocrinology 25 503-515. (doi:10.1210/me.2010-0340)
100. Sampson N, Ruiz C, Zenzmaier C, Bubendorf L & Berger P 2012 PAGE4 positivity is associated with attenuated AR signaling and predicts patient survival in hormone-naive prostate cancer. American Journal of Pathology 181 1443-1454. (doi:10.1016/j.ajpath.2012.06.040)
101. Schaufele F, Carbonell X, Guerbadot M, Borngraeber S, Chapman MS, Ma AA, Miner JN & Diamond MI 2005 The structural basis of androgen receptor activation: intramolecular and intermolecular amino-carboxy interactions. PNAS 102 9802-9807. (doi:10.1073/pnas.0408819102)
102. Schweizer MT & Antonarakis ES 2012 Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born. Therapeutic Advances in Urology 4 167-178. (doi:10.1177/1756287212452196)
103. Sharma NL, Massie CE, Ramos-Montoya A, Zecchini V, Scott HE, Lamb AD, Macarthur S, Stark R, Warren AY, Mills IG et al. 2013 The androgen receptor induces a distinct transcriptional program in castrationresistant prostate cancer in man. Cancer Cell 23 35-47. (doi:10.1016/j.ccr.2012.11.010)
104. Shaw A, Papadopoulos J, Johnson C & BushmanW2006 Isolation and characterization of an immortalized mouse urogenital sinus mesenchyme cell line. Prostate 66 1347-1358. (doi:10.1002/pros.20357)
105. Siegel R, Naishadham D & Jemal A 2012 Cancer statistics, 2012. CA: A Cancer Journal for Clinicians 62 10-29. (doi:10.3322/caac.20138)
106. Sieh S, Lubik AA, Clements JA, Nelson CC & Hutmacher DW 2010 Interactions between human osteoblasts and prostate cancer cells in a novel 3D in vitro model. Organogenesis 6 181-188. (doi:10.4161/org.6.3.12041)
107. Sieh S, Taubenberger AV, Rizzi SC, Sadowski M, Lehman ML, Rockstroh A, An J, Clements JA, Nelson CC & Hutmacher DW 2012 Phenotypic characterization of prostate cancer LNCaP cells cultured within a bioengineered microenvironment. PLoS ONE 7 e40217. (doi:10.1371/journal.pone.0040217)
108. Smith DF & Toft DO 1993 Steroid receptors and their associated proteins. Molecular Endocrinology 7 4-11. (doi:10.1210/me.7.1.4)
109. Snoek R, Cheng H, Margiotti K, Wafa LA, Wong CA, Wong EC, Fazli L, Nelson CC, Gleave ME & Rennie PS 2009 In vivo knockdown of the androgen receptor results in growth inhibition and regression of wellestablished, castration-resistant prostate tumors. Clinical Cancer Research 15 39-47. (doi:10.1158/1078-0432.CCR-08-1726)
110. Spans L, Atak ZK, Van Nieuwerburgh F, Deforce D, Lerut E, Aerts S & Claessens F 2012 Variations in the exome of the LNCaP prostate cancer cell line. Prostate 72 1317-1327. (doi:10.1002/pros.22480)
111. Sramkoski RM, Pretlow TG, II, Giaconia JM, Pretlow TP, Schwartz S, Sy MS, Marengo SR, Rhim JS, Zhang D & Jacobberger JW 1999 A new human prostate carcinoma cell line, 22Rv1. In Vitro Cellular & Developmental Biology. Animal 35 403-409. (doi:10.1007/s11626-999-0115-4)
112. Stangelberger A, Schally AV, Rick FG, Varga JL, Baker B, Zarandi M & Halmos G 2012 Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild-type p53 and decrease in p21 and mutant p53 proteins. Prostate 72 555-565. (doi:10.1002/pros.21458)
113. Steinkamp MP, O'Mahony OA, Brogley M, Rehman H, Lapensee EW, Dhanasekaran S, Hofer MD, Kuefer R, Chinnaiyan A, Rubin MA et al. 2009 Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. Cancer Research 69 4434-4442. (doi:10.1158/0008-5472.CAN-08-3605)
114. Stepanenko AA & Kavsan VM 2012 Immortalization and malignant transformation of eukaryotic cells. Cytology and Genetics 46 36-75. (doi:10.3103/S0095452712020041)
115. Stone KR, Mickey DD, Wunderli H, Mickey GH & Paulson DF 1978 Isolation of a human prostate carcinoma cell line (DU 145). International Journal of Cancer 21 274-281. (doi:10.1002/ijc. 2910210305)
116. Tanner MJ, Welliver RC, Jr., Chen M, Shtutman M, Godoy A, Smith G, Mian BM & Buttyan R 2011 Effects of androgen receptor and androgen on gene expression in prostate stromal fibroblasts and paracrine signaling to prostate cancer cells. PLoS ONE 6 e16027. (doi:10.1371/journal.pone.0016027)
117. Tekur S, Lau KM, Long J, Burnstein K & Ho SM 2001 Expression of RFG/ELE1a/ARA70 in normal and malignant prostatic epithelial cell cultures and lines: regulation by methylation and sex steroids. Molecular Carcinogenesis 30 1-13. (doi:10.1002/1098-2744(200101)30:1!1::AID-MC1008O3.0.CO;2-X)
118. Thalmann GN, Anezinis PE, Chang S-M, Zhau HE, Kim EE, Hopwood VL, Pathak S, von Eschenbach AC & Chung LWK 1994 Androgenindependent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Research 54 2577-2581.
119. Thalmann GN, Sikes RA, Wu TT, Degeorges A, Chang SM, OzenM, Pathak S & Chung LW 2000 LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis. Prostate 44 91-103 (Jul 101; 144 (102)). (doi:10.1002/1097-0045(20000701)44:2!91::AID-PROS1O3.0.CO;2-L)
120. Thomas P 2012 Rapid steroid hormone actions initiated at the cell surface and the receptors that mediate them with an emphasis on recent progress in fish models. General and Comparative Endocrinology 175 367-383. (doi:10.1016/j. ygcen.2011.11.032)
121. Toivanen R, Taylor RA, Pook DW, Ellem SJ & Risbridger GP 2012 Breaking through a roadblock in prostate cancer research: an update on human model systems. Journal of Steroid Biochemistry and Molecular Biology 131 122-131. (doi:10.1016/j.jsbmb.2012.01.005)
122. Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, Helgeson BE, Cao Q, Prensner JR, Rubin MA, Shah RB et al. 2008 Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 10 177-188. (doi:10.1593/neo.07822)
123. Truss M & Beato M 1993 Steroid hormone receptors: interaction with deoxyribonucleic acid and transcription factors. Endocrine Reviews 14 459-479.
124. Tsai MJ & O'Malley BW 1994 Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annual Review of Biochemistry 63 451-486. (doi:10.1146/annurev.bi.63.070194.002315)
125. Tso CL, McBride WH, Sun J, Patel B, Tsui KH, Paik SH, Gitlitz B, Caliliw R, van Ophoven A, Wu L et al. 2000 Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells. Cancer Journal 6 220-233.
126. Untergasser G, Plas E, Pfister G, Heinrich E & Berger P 2005 Interferon-g induces neuroendocrine-like differentiation of human prostate basalepithelial cells. Prostate 64 419-429. (doi:10.1002/pros.20261)
127. Urbanucci A, Sahu B, Seppala J, Larjo A, Latonen LM, Waltering KK, Tammela TL, Vessella RL, Lahdesmaki H, Janne OA et al. 2012 Overexpression of androgen receptor enhances the binding of the receptor to the chromatin in prostate cancer. Oncogene 31 2153-2163. (doi:10.1038/onc.2011.401)
128. Veldscholte J, Voorhorst-Ogink MM, Bolt-de Vries J, van Rooij HCJ, Trapman J & Mulder E 1990 Unusual specificity of the androgen receptor in the human prostate tumor cell line LNCaP: high affinity for progestagenic and
129. Veldscholte J, Berrevoets CA, Zegers ND, van der Kvast TH, Grootegoed JA & Mulder E 1992 Hormone-induced dissociation of the androgen receptor-heat-shock protein complex. Use of a new monoclonal antibody to distinguish transformed from nontransformed receptors. Biochemistry 31 7422-7430. (doi:10.1021/bi00147a029)
130. Verona EV, Elkahloun AG, Yang J, Bandyopadhyay A, Yeh IT& Sun LZ 2007 Transforming growth factor-b signaling in prostate stromal cells supports prostate carcinoma growth by up-regulating stromal genes related to tissue remodeling. Cancer Research 67 5737-5746. (doi:10.1158/0008-5472.CAN-07-0444)
131. Waltering KK, Helenius MA, Sahu B, Manni V, Linja MJ, Janne OA & Visakorpi T 2009 Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Research 69 8141-8149. (doi:10.1158/0008-5472.CAN-09-0919)
132. Wang R, Xu J, Juliette L, Castilleja A, Love J, Sung SY, Zhau HE, Goodwin TJ & Chung LW 2005 Three-dimensional co-culture models to study prostate cancer growth, progression, and metastasis to bone. Seminars in Cancer Biology 15 353-364. (doi:10.1016/j.semcancer.2005.005)
133. Wang R, Sun X,Wang CY, Hu P, Chu CY, Liu S, Zhau HE & Chung LW 2012 Spontaneous cancer-stromal cell fusion as a mechanism of prostate cancer androgen-independent progression. PLoS ONE 7 e42653. (doi:10.1371/journal.pone. 0042653)
134. Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, Kim K & Sawyers CL 2010 Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require fulllength androgen receptor. PNAS 107 16759-16765. (doi:10.1073/pnas. 1012443107)
135. Webber MM, Bello D, Kleinman HK, Wartinger DD, Williams DE & Rhim JS 1996a Prostate specific antigen and androgen receptor induction and characterization of an immortalized adult human prostatic epithelial cell line. Carcinogenesis 17 1641-1646. (doi:10.1093/carcin/17.8.1641)
136. Webber MM, Bello D & Quader S 1996b Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications. Part I. Cell markers and immortalized nontumorigenic cell lines. Prostate 29 386-394. (doi:10.1002/(SICI)1097-0045(199612)29:6!386::AID-PROS7O3.0.CO;2-6)
137. Webber MM, Trakul N, Thraves PS, Bello-DeOcampo D, Chu WW, Storto PD, Huard TK, Rhim JS & Williams DE 1999 A human prostatic stromalmyofibroblast cell line WPMY-1: a model for stromal-epithelial interactions in prostatic neoplasia. Carcinogenesis 20 1185-1192. (doi:10.1093/carcin/20.7.1185)
138. Webber MM, Quader ST, Kleinman HK, Bello-DeOcampo D, Storto PD, Bice G, DeMendonca-CalacaW& Williams DE 2001 Human cell lines as an in vitro/in vivo model for prostate carcinogenesis and progression. Prostate 47 1-13. (doi:10.1002/pros.1041)
139. Wegiel B, Evans S, Hellsten R, Otterbein LE, Bjartell A & Persson JL 2010 Molecular pathways in the progression of hormone-independent and metastatic prostate cancer. Current Cancer Drug Targets 10 392-401. (doi:10.2174/ 156800910791208562)
140. Wilson JD 1996 Role of dihydrotestosterone in androgen action. Prostate. Supplement 6 88-92. (doi:10.1002/(SICI)1097-0045(1996)6C!88::AIDPROS17O3.0.CO;2- N)
141. Xu X, Gurski LA, Zhang C, Harrington DA, Farach-Carson MC & Jia X 2012 Recreating the tumor microenvironment in a bilayer, hyaluronic acid hydrogel construct for the growth of prostate cancer spheroids. Biomaterials 33 9049-9060. (doi:10.1016/j.biomaterials. 2012.08.061)
142. Yadav N & Heemers HV 2012 Androgen action in the prostate gland. Minerva Urologica e Nefrologica 64 35-49.
143. Yu S, Wang MW, Yao X & Chan FL 2009 Establishment of a novel immortalized human prostatic epithelial cell line stably expressing androgen receptor and its application for the functional screening of androgen receptor modulators. Biochemical and Biophysical Research Communications 382 756-761. (doi:10.1016/j.bbrc. 2009.03.110)
144. Yu C, Yao Z, Jiang Y & Keller ET 2012 Prostate cancer stem cell biology. Minerva Urologica e Nefrologica 64 19-33.
145. Zhao XY, Boyle B, Krishnan AV, Navone NM, Peehl DM & Feldman D 1999 Two mutations identified in the androgen receptor of the new human prostate cancer cell lineMDA PCa 2a. Journal of Urology 162 2192-2199. (doi:10.1016/S0022-5347(05)68158-X)
146. Zhau HYE, Chang S-M, Chen B-Q, Wang Y, Zhang H, Kao C, Sang QA, Pathak SJ & Chung LWK 1996 Androgen-repressed phenotype in human prostate cancer. PNAS 93 15152-15157. (doi:10.1073/pnas.93.26.15152)
147. Zhau HE, Goodwin TJ, Chang SM, Baker TL & Chung LW 1997 Establishment of a three-dimensional human prostate organoid coculture under microgravity-simulated conditions: evaluation of androgen-induced growth and PSA expression. In Vitro Cellular & Developmental Biology. Animal 33 375-380. (doi:10.1007/s11626-997-0008-3)